vs
德康医疗（DXCM）与美泰（MAT）财务数据对比。点击上方公司名可切换其他公司
美泰的季度营收约是德康医疗的1.4倍（$1.8B vs $1.3B），德康医疗净利率更高（21.2% vs 6.0%，领先15.2%），德康医疗同比增速更快（21.6% vs 7.3%），过去两年美泰的营收复合增速更高（47.7% vs 12.0%）
德康医疗是美国跨国医疗保健企业，专注于研发、生产及销售糖尿病管理领域的连续血糖监测（CGM）系列系统。其全球总部及研发中心位于美国加利福尼亚州圣地亚哥，生产基地分布于美国亚利桑那州梅萨、马来西亚峇都交湾及爱尔兰戈尔韦郡阿斯里。
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
DXCM vs MAT — 直观对比
营收规模更大
MAT
是对方的1.4倍
$1.3B
营收增速更快
DXCM
高出14.3%
7.3%
净利率更高
DXCM
高出15.2%
6.0%
两年增速更快
MAT
近两年复合增速
12.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $1.8B |
| 净利润 | $267.3M | $106.2M |
| 毛利率 | 62.9% | 45.9% |
| 营业利润率 | 25.6% | 8.0% |
| 净利率 | 21.2% | 6.0% |
| 营收同比 | 21.6% | 7.3% |
| 净利润同比 | 153.6% | -24.6% |
| 每股收益（稀释后） | $0.67 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DXCMMAT
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $1.8B | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.2B | $1.0B | ||
| Q1 25 | $1.0B | $826.6M | ||
| Q4 24 | $1.1B | $1.6B | ||
| Q3 24 | $994.2M | $1.8B | ||
| Q2 24 | $1.0B | $1.1B |
净利润DXCMMAT
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | $106.2M | ||
| Q3 25 | $283.8M | $278.4M | ||
| Q2 25 | $179.8M | $53.4M | ||
| Q1 25 | $105.4M | $-40.3M | ||
| Q4 24 | $151.7M | $140.9M | ||
| Q3 24 | $134.6M | $372.4M | ||
| Q2 24 | $143.5M | $56.9M |
毛利率DXCMMAT
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | 45.9% | ||
| Q3 25 | 60.5% | 50.0% | ||
| Q2 25 | 59.5% | 50.9% | ||
| Q1 25 | 56.9% | 49.4% | ||
| Q4 24 | 58.9% | 50.7% | ||
| Q3 24 | 59.7% | 53.1% | ||
| Q2 24 | 62.4% | 49.2% |
营业利润率DXCMMAT
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 8.0% | ||
| Q3 25 | 20.1% | 21.9% | ||
| Q2 25 | 18.4% | 7.7% | ||
| Q1 25 | 12.9% | -6.4% | ||
| Q4 24 | 17.0% | 9.6% | ||
| Q3 24 | 15.3% | 26.5% | ||
| Q2 24 | 15.7% | 7.7% |
净利率DXCMMAT
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | 6.0% | ||
| Q3 25 | 23.5% | 16.0% | ||
| Q2 25 | 15.5% | 5.2% | ||
| Q1 25 | 10.2% | -4.9% | ||
| Q4 24 | 13.6% | 8.6% | ||
| Q3 24 | 13.5% | 20.2% | ||
| Q2 24 | 14.3% | 5.3% |
每股收益（稀释后）DXCMMAT
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $0.32 | ||
| Q3 25 | $0.70 | $0.88 | ||
| Q2 25 | $0.45 | $0.16 | ||
| Q1 25 | $0.27 | $-0.12 | ||
| Q4 24 | $0.37 | $0.40 | ||
| Q3 24 | $0.34 | $1.09 | ||
| Q2 24 | $0.35 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $917.7M | $1.2B |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $2.7B | $2.2B |
| 总资产 | $6.3B | $6.6B |
| 负债/权益比越低杠杆越低 | — | 1.04× |
8季度趋势，按日历期对齐
现金及短期投资DXCMMAT
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $1.2B | ||
| Q3 25 | $1.8B | $691.9M | ||
| Q2 25 | $1.2B | $870.5M | ||
| Q1 25 | $904.9M | $1.2B | ||
| Q4 24 | $606.1M | $1.4B | ||
| Q3 24 | $621.2M | $723.5M | ||
| Q2 24 | $939.2M | $722.4M |
总债务DXCMMAT
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.3B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.3B |
股东权益DXCMMAT
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $2.2B | ||
| Q3 25 | $2.7B | $2.3B | ||
| Q2 25 | $2.6B | $2.2B | ||
| Q1 25 | $2.3B | $2.1B | ||
| Q4 24 | $2.1B | $2.3B | ||
| Q3 24 | $2.0B | $2.3B | ||
| Q2 24 | $2.4B | $2.0B |
总资产DXCMMAT
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $6.6B | ||
| Q3 25 | $7.5B | $6.6B | ||
| Q2 25 | $7.3B | $6.2B | ||
| Q1 25 | $6.8B | $6.2B | ||
| Q4 24 | $6.5B | $6.5B | ||
| Q3 24 | $6.4B | $6.5B | ||
| Q2 24 | $6.8B | $5.9B |
负债/权益比DXCMMAT
| Q1 26 | — | — | ||
| Q4 25 | — | 1.04× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.08× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.03× | ||
| Q3 24 | — | 1.01× | ||
| Q2 24 | — | 1.18× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $796.6M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 7.50× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DXCMMAT
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $796.6M | ||
| Q3 25 | $659.9M | $72.0M | ||
| Q2 25 | $303.0M | $-300.1M | ||
| Q1 25 | $183.8M | $24.8M | ||
| Q4 24 | $301.4M | $862.1M | ||
| Q3 24 | $199.5M | $155.8M | ||
| Q2 24 | $279.4M | $-252.9M |
自由现金流DXCMMAT
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | — | ||
| Q3 25 | $579.4M | — | ||
| Q2 25 | $208.9M | — | ||
| Q1 25 | $96.8M | — | ||
| Q4 24 | $176.8M | — | ||
| Q3 24 | $88.3M | — | ||
| Q2 24 | $213.3M | — |
自由现金流率DXCMMAT
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | — | ||
| Q3 25 | 47.9% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 15.9% | — | ||
| Q3 24 | 8.9% | — | ||
| Q2 24 | 21.2% | — |
资本支出强度DXCMMAT
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | — | ||
| Q3 25 | 6.7% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 8.4% | — | ||
| Q4 24 | 11.2% | — | ||
| Q3 24 | 11.2% | — | ||
| Q2 24 | 6.6% | — |
现金转化率DXCMMAT
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 7.50× | ||
| Q3 25 | 2.33× | 0.26× | ||
| Q2 25 | 1.69× | -5.62× | ||
| Q1 25 | 1.74× | — | ||
| Q4 24 | 1.99× | 6.12× | ||
| Q3 24 | 1.48× | 0.42× | ||
| Q2 24 | 1.95× | -4.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DXCM
暂无分部数据
MAT
| North America Segment | $1.0B | 58% |
| International Segment | $745.6M | 42% |
